AR037687A1 - Composiciones farmaceuticas a base de derivados de azetidina - Google Patents
Composiciones farmaceuticas a base de derivados de azetidinaInfo
- Publication number
- AR037687A1 AR037687A1 ARP020104646A ARP020104646A AR037687A1 AR 037687 A1 AR037687 A1 AR 037687A1 AR P020104646 A ARP020104646 A AR P020104646A AR P020104646 A ARP020104646 A AR P020104646A AR 037687 A1 AR037687 A1 AR 037687A1
- Authority
- AR
- Argentina
- Prior art keywords
- azetidine
- derivative
- general formula
- pharmaceutical compositions
- derivatives
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical class C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 title 1
- 150000001539 azetidines Chemical class 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000084 colloidal system Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composición farmacéutica estable, que comprende al menos un derivado de azetidina de fórmula general (ia) o (ib) en la que Ar es un grupo aromático o heteroaromático, eventualmente substituido por uno o varios alquilo ( con 1 a 4 átomos de carbono ), halógeno, NO2, CN, alcoxi ( con 1 a 4 átomos de carbono ) o OH, eventualmente en asociación con otro principio activo, capaz de potencializar los efectos del derivado de azetidina de fórmula general (ia) o (ib), en un sistema que comprende como máximo dos excipientes principales elegidos entre un agente tensioactivo no iónico de carácter hidrófilo, capas de solubilizar el derivado de azetidina de fórmula general (ia) o (ib) y, en caso dado, el principio activo que potencializa los efectos del derivado de azetidina, y capaz de provocar la formación de un sistema coloidal, combinado, eventualmente, con un segundo excipiente de naturaleza lipófila, que estabilice la formulación. Las composiciones farmacéuticas, que comprenden derivados de azetidina de las fórmulas (ia) o (ib), son particularmente interesantes, debido a la fuerte afinadad de estos derivados para los receptores cannabinoides.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0116638A FR2833842B1 (fr) | 2001-12-21 | 2001-12-21 | Compositions pharmaceutiques a base de derives d'azetidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037687A1 true AR037687A1 (es) | 2004-12-01 |
Family
ID=8870824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104646A AR037687A1 (es) | 2001-12-21 | 2002-12-02 | Composiciones farmaceuticas a base de derivados de azetidina |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1458413B1 (es) |
| JP (1) | JP5021887B2 (es) |
| KR (1) | KR20040068308A (es) |
| CN (1) | CN100388918C (es) |
| AP (1) | AP1754A (es) |
| AR (1) | AR037687A1 (es) |
| AU (1) | AU2002364866B2 (es) |
| BR (1) | BR0215048A (es) |
| CA (1) | CA2470443A1 (es) |
| CO (1) | CO5590911A2 (es) |
| DE (1) | DE60233071D1 (es) |
| DK (1) | DK1458413T3 (es) |
| EA (1) | EA006510B1 (es) |
| EC (1) | ECSP045162A (es) |
| FR (1) | FR2833842B1 (es) |
| HR (1) | HRP20040575A2 (es) |
| HU (1) | HUP0402586A3 (es) |
| IL (1) | IL162563A0 (es) |
| MA (1) | MA27086A1 (es) |
| ME (1) | MEP16608A (es) |
| MX (1) | MXPA04005558A (es) |
| MY (1) | MY138172A (es) |
| NO (1) | NO20042781L (es) |
| NZ (1) | NZ533225A (es) |
| OA (1) | OA12750A (es) |
| PL (1) | PL203248B1 (es) |
| RS (1) | RS55504A (es) |
| TW (1) | TWI256304B (es) |
| UA (1) | UA77736C2 (es) |
| WO (1) | WO2003053431A2 (es) |
| ZA (1) | ZA200404338B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1498123A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Emulsifying systems containing azetidine derivatives |
| EP1498122A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid systems containing azetidine derivatives |
| RU2006133258A (ru) | 2004-02-17 | 2008-04-10 | Лабораториос Дель Др. Эстеве С.А. (Es) | Замещенные азетидиновые производные, их получение и применение в качестве лекарственных средств |
| FR2879932B1 (fr) * | 2004-12-27 | 2007-03-23 | Aventis Pharma Sa | Formulations injectable ou administrable par voie orale de derives d'azetidine |
| MX2007016508A (es) | 2005-06-30 | 2008-03-04 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g. |
| CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| BRPI0806312A2 (pt) | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
| RS52065B (sr) | 2007-01-04 | 2012-06-30 | Prosidion Ltd | Piperidinski gpcr agonisti |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| FR2923719B1 (fr) * | 2007-11-15 | 2009-11-20 | Sanofi Aventis | Compositions pharmaceutiques a base de derives d'azetidine |
| FR2928149B1 (fr) | 2008-02-29 | 2011-01-14 | Sanofi Aventis | Composes derives d'azetidines, leur preparation et leur application en therapeutique |
| FR2946650B1 (fr) * | 2009-06-16 | 2011-08-19 | Sanofi Aventis | Esters derives d'azetidines, leur preparation et leur application en therapeutique. |
| UA153183U (uk) | 2022-10-27 | 2023-05-31 | Андрій Валерійович Максимов | Стаканчик для приготування напою |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR73668B (es) * | 1978-11-21 | 1984-03-28 | Hoffmann La Roche | |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| HRP980026A2 (en) * | 1998-01-20 | 1999-10-31 | Pliva Pharm & Chem Works | 1-izothiazolydinone derivatives of azetidine-2-ones, processes for the preparation and use thereof |
| AU4989299A (en) * | 1998-07-14 | 2000-02-07 | Em Industries, Inc. | Microdisperse drug delivery systems |
| FR2783246B1 (fr) * | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
-
2001
- 2001-12-21 FR FR0116638A patent/FR2833842B1/fr not_active Expired - Fee Related
-
2002
- 2002-12-02 AR ARP020104646A patent/AR037687A1/es unknown
- 2002-12-03 TW TW091135077A patent/TWI256304B/zh active
- 2002-12-20 IL IL16256302A patent/IL162563A0/xx unknown
- 2002-12-20 EP EP02801165A patent/EP1458413B1/fr not_active Expired - Lifetime
- 2002-12-20 NZ NZ533225A patent/NZ533225A/en not_active IP Right Cessation
- 2002-12-20 OA OA1200400178A patent/OA12750A/fr unknown
- 2002-12-20 AU AU2002364866A patent/AU2002364866B2/en not_active Ceased
- 2002-12-20 DK DK02801165T patent/DK1458413T3/da active
- 2002-12-20 BR BR0215048-4A patent/BR0215048A/pt not_active IP Right Cessation
- 2002-12-20 JP JP2003554188A patent/JP5021887B2/ja not_active Expired - Fee Related
- 2002-12-20 UA UA20040706001A patent/UA77736C2/uk unknown
- 2002-12-20 HU HU0402586A patent/HUP0402586A3/hu unknown
- 2002-12-20 DE DE60233071T patent/DE60233071D1/de not_active Expired - Lifetime
- 2002-12-20 MY MYPI20024828A patent/MY138172A/en unknown
- 2002-12-20 PL PL372708A patent/PL203248B1/pl not_active IP Right Cessation
- 2002-12-20 EA EA200400843A patent/EA006510B1/ru not_active IP Right Cessation
- 2002-12-20 WO PCT/FR2002/004514 patent/WO2003053431A2/fr not_active Ceased
- 2002-12-20 KR KR10-2004-7009708A patent/KR20040068308A/ko not_active Ceased
- 2002-12-20 MX MXPA04005558A patent/MXPA04005558A/es active IP Right Grant
- 2002-12-20 RS YUP-555/04A patent/RS55504A/sr unknown
- 2002-12-20 AP APAP/P/2004/003066A patent/AP1754A/en active
- 2002-12-20 HR HR20040575A patent/HRP20040575A2/hr not_active Application Discontinuation
- 2002-12-20 CN CNB028248406A patent/CN100388918C/zh not_active Expired - Fee Related
- 2002-12-20 CA CA002470443A patent/CA2470443A1/fr not_active Abandoned
- 2002-12-20 ME MEP-166/08A patent/MEP16608A/xx unknown
-
2004
- 2004-05-21 MA MA27694A patent/MA27086A1/fr unknown
- 2004-06-02 ZA ZA200404338A patent/ZA200404338B/en unknown
- 2004-06-17 CO CO04056913A patent/CO5590911A2/es not_active Application Discontinuation
- 2004-06-18 EC EC2004005162A patent/ECSP045162A/es unknown
- 2004-07-01 NO NO20042781A patent/NO20042781L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037687A1 (es) | Composiciones farmaceuticas a base de derivados de azetidina | |
| AR037951A1 (es) | Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada | |
| BRPI0416752B8 (pt) | composição farmacêutica, uso de um ou mais compostos, e, compostos | |
| CO5640125A2 (es) | Composicion inhibidora selectiva de la ciclooxigenasa-2 permeable en la piel | |
| CO5560559A2 (es) | Formulacion de suspension oral estabilizada | |
| NO20000466L (no) | Farmasøytisk preparat for sure, lipofile forbindelser i form av en selvregulerende formulering | |
| CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
| BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| CO5580835A2 (es) | Nuevas formulaciones analogas de ciclosporina | |
| ECSP014097A (es) | Derivados de tiofeno utiles como agentes anticancerosos | |
| IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
| AR099754A2 (es) | Composición farmacéutica agonista de subtipo de receptor 5-ht₁a | |
| AR036248A1 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| AR021370A1 (es) | Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides | |
| PA8495101A1 (es) | Derivados de 13-metileritromicina | |
| BRPI0417161A (pt) | compostos, composições farmacêuticas, e, uso de um composto | |
| CO5540294A2 (es) | Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen | |
| AR035110A1 (es) | Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto | |
| AR045912A1 (es) | Composiciones farmaceuticas que contienen derivados de azetidina | |
| JP4979258B2 (ja) | アシタザノラスト含有水性組成物 | |
| AR045911A1 (es) | Formulaciones auto-emulsionables y formulaciones auto-microemulsionables para la administracion oral de taxoides | |
| BR0312817A (pt) | Composição de pomada oftálmica compreendendo uma droga, uma base de pomada e um agente solubilizante/dispersante | |
| BRPI0414494A (pt) | compostos, composições farmacêuticas, e, uso de um composto | |
| UY26459A1 (es) | 3,4-dihidroquinazolinas 5,6-disustituidas | |
| JP5052028B2 (ja) | アシタザノラスト含有組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |